[SCHEDULE 13D/A] Vor Biopharma Inc. SEC Filing

Rhea-AI Filing Summary

Amendment No. 2 to Schedule 13D discloses that Reprogrammed Interchange LLC and Reid Hoffman collectively beneficially own 35,476,939 shares of Vor Biopharma Inc., representing 28.0% of the outstanding common stock. The amendment reports open-market sales by Reprogrammed Interchange LLC from August 25, 2025 through September 5, 2025 that reduced the reporting persons' stake by more than one percentage point. Recent dispositions total 3,497,162 shares sold in multiple transactions at weighted average prices around $2.00 per share. The filing amends prior Schedule 13D disclosures and otherwise leaves earlier statements unchanged.

Positive

• Full disclosure of recent transactions with dates, share counts, and weighted average prices provides transparency to the market
• Large residual stake remains: Reporting Persons continue to beneficially own 35,476,939 shares, representing 28.0% of the class

Negative

• Substantial open-market sales totaling 3,497,162 shares between August 25 and September 5, 2025, which reduced the Reporting Persons' holdings
• Concentrated selling occurred over a short period at weighted average prices near $2.00 per share

Insights

Securities Analyst

TL;DR: Significant insider-related selling reduced a large 28.0% position through block open-market trades near $2.00 per share.

Reprogrammed Interchange LLC and Reid Hoffman remain the beneficial owners of 35,476,939 shares (28.0%). The amendment itemizes recent, concentrated open-market sales totaling 3,497,162 shares executed between August 25 and September 5, 2025, with weighted average sale prices roughly in the $1.93–$2.12 range. For investors, the filing signals active disposition from a major holder and provides clear transaction-level detail; it does not describe any change in intent or new arrangements beyond the reported sales.

Corporate Governance Expert

TL;DR: Reporting persons continue to disclose material changes; large share sales are documented but no new agreements or control changes are reported.

The amendment is focused on disclosure compliance: it supplements Item 4 and Item 5 to report multiple open-market sales and restates the aggregate beneficial ownership. There are no stated contracts, arrangements, or other understandings (Item 6 is "Not applicable"), and no legal proceedings disclosed. The filing therefore documents material transfers of stock without indicating any coordinated change in governance or new strategic arrangements.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)

VOR BIOPHARMA INC.

(Name of Issuer)

Common Stock, par value $.0001 per share

(Title of Class of Securities)

929033108

(CUSIP Number)

Frank Huang, Manager
101 Mission Street, Suite 1000,
San Francisco, CA, 94105
(415) 541-0200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/05/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 929033108

1

Name of reporting person

Reprogrammed Interchange LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 35,476,939.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 35,476,939.00

11

Aggregate amount beneficially owned by each reporting person

35,476,939.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

28.0 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 929033108

1

Name of reporting person

Reid Hoffman

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 35,476,939.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 35,476,939.00

11

Aggregate amount beneficially owned by each reporting person

35,476,939.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

28.0 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $.0001 per share
(b)	Name of Issuer: VOR BIOPHARMA INC.
(c)	Address of Issuer's Principal Executive Offices: 100 Cambridgepark Drive, Suite 101, Cambridge, MASSACHUSETTS , 02140.
Item 1 Comment: This Amendment No. 2 to Schedule 13D amends and supplements the information provided in the previously filed Statement on Schedule 13D filed with the Securities and Exchange Commission on January 7, 2025 and in Amendment No. 1 thereto filed with the Securities and Exchange Commission on August 29, 2025 (collectively, the "Schedule 13D"), jointly on behalf of Reprogrammed Interchange LLC and Reid Hoffman (each a "Reporting Person" and collectively, the "Reporting Persons"). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain unchanged in all material respects and in full force and effect. Capitalized terms used but not defined herein have the meaning ascribed to such term in the Schedule 13D, as amended. Responses to each item of this Amendment No. 2 to Schedule 13D are incorporated by reference into the response to each other item, as applicable.
Item 3.	Source and Amount of Funds or Other Consideration
	Not applicable.
Item 4.	Purpose of Transaction
	Item 4 of Schedule 13D is hereby amended and supplemented as follows: From September 3, 2025 through September 5, 2025, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions, resulting in a decrease in the number of shares of Common Stock beneficially owned by the Reporting Persons by more than one percent of the outstanding shares of Common Stock of the Issuer: 1. 554,612 shares on September 3, 2025, at a weighted average per share sale price of $1.9961. 2. 453,016 shares on September 4, 2025, at a weighted average per share sale price of $1.9285. 3. 400,000 shares on September 5, 2025, at a weighted average per share sale price of $1.9682.
Item 5.	Interest in Securities of the Issuer
(a)	The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Amendment No. 2 to the Schedule 13D, and the information set forth or incorporated in Items 2, 3, 4, 6 and 7, is incorporated by reference in its entirety into this Item 5.
(b)	Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets, (ii) shared power to vote or to direct the vote: See line 8 of cover sheets, (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets, and (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.
(c)	During the past 60 days, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions: 1. 387,346 shares on August 25, 2025, at a weighted average per share sale price of $2.1163. 2. 284,190 shares on August 26, 2025, at a weighted average per share sale price of $2.0808. 3. 611,647 shares on August 27, 2025, at a weighted average per share sale price of $2.0053. 4. 806,351 shares on August 28, 2025, at a weighted average per share sale price of $2.0115.
(d)	Not applicable.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Reprogrammed Interchange LLC

Signature:	/s/ Frank Huang
Name/Title:	Frank Huang, Manager
Date:	09/09/2025

Reid Hoffman

Signature:	/s/ Reid Hoffman
Name/Title:	Reid Hoffman
Date:	09/09/2025

FAQ

How many Vor Biopharma (VOR) shares do the reporting persons now beneficially own?

The reporting persons beneficially own 35,476,939 shares, representing 28.0% of VOR's outstanding common stock.

What trades did Reprogrammed Interchange LLC report in this amendment?

The amendment lists open-market sales including 3,497,162 total shares sold on specified dates between August 25 and September 5, 2025, with weighted average prices around $1.93–$2.12 per share.

Did the filing disclose any new agreements or arrangements regarding VOR stock?

No. Item 6 states Not applicable, and the amendment does not disclose any contracts, arrangements, or understandings.

Are there any legal proceedings disclosed in the filing?

No. The cover page indicates that disclosure of legal proceedings pursuant to Items 2(d) or 2(e) is not checked, and no proceedings are described.

Who signed this Amendment No. 2 to Schedule 13D?

The filing is signed by Frank Huang for Reprogrammed Interchange LLC (Manager) and by Reid Hoffman individually, each dated September 9, 2025.